Articles On Exopharm (ASX:EX1)

Biotech tends to follow a four to five year market cycle and those in the sector say there are signals that the next upturn has begun. That was the message today as four biotech companies and Life Sciences WA presented to 200 brokers and...

What stocks trading at 52-week highs are telling us How do we know if they are overbought or oversold? We take a look at one investing strategy called the 52-Week High Rotation Strategy   One indicator used by chartists to determine an en...

ASX 200 closes significantly lower Mining Sector sheds -3.2% after BHP goes ex-div Small caps led by huge LPM find   I’m usually the first to kick the Australian sharemarket when its down, but the kind of losses the ASX200’s been handin...

ASX dips 0.56% despite a solid kickstart first thing this morning InfoTech outperforms the market again, leading on +0.21% for the day Heavy Minerals banks a 90% bump on some big time garnet news   For 10 fantastic minutes this morning, l...

The S&P ASX 200 was down 2.5% in May, with mid caps performing the best and small caps lagging blue chips The S&P ASX 200 Information Technology sector performed the best in May, up 11.6% following strong AI interest Wildcat Resou...

ASX benchmark ends the day flat, but not for lack of trying to rise. Or fall Tech stocks fell hard at first light, but rallied to finish the day well out in front Despite a short-lived challenge from Audio Pixels, Micro-X has won the day i...

RBA Board kicks the nation in the goolies again, demanding another 25 basis points Investors seemingly caught by surprise, tanking the market in a matter of minutes Pinnacle Minerals let off the leash by the ASX, but still ahead of the gam...

The S&P ASX 200 finished up 1.85% in April while mid and small caps outperformed their blue-chip peers Real estate topped the winning sectors for the month while tech stocks also rallied strongly in April Gold stocks continued solid ru...

The benchmark kicked off well at +0.8% before deflating to finish on +0.4% Utilities (+1.21%)win the day, while InfoTech (-1.20%) takes a body blow. Lincoln Minerals (ASX:LML) tops the charts, up 36% for absolutely no reason at all.   Loc...

The S&P ASX 200 follows US markets closing fairly flat up 0.07%, while the S&P XEC is up 0.53% Pinnacle Minerals accidentally discovers rare earths at the Disruptor Prospect  Wide Open Agriculture gives positive business update, re...

ASX closes up 0.78%, while XEC rises 1.91% following global markets higher Morningstar warns of possible start of US recession next week spanning 3 quarters, but talk of pause in Aussie rate hikes ‘premature’ Hubify subsidiary Broadland So...

Benchmark set to finish close to flat as Energy stocks slump again Goldies are surging again, with that sector up 1.3% for the day Even the big banks are bracing for trouble with talk of a crisis getting louder by the day   After a modera...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX down, then up, then down even further to -1.4% as bank crisis looms large. XEC Emerging Companies index plummets 1.8% as fear overtakes greed. Goldies are making hay again, XED All Ordinaries Gold up more than 7.0%.   Things have been...

ASX 200 adds just 0.1% because it was literally the least it could do. Aussie tech stock surge negated by Doctors and Miners having a bad hair day. Two ASX-listed lithium players are under attack over alleged corruption in Africa, of all p...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

RooLife is today’s ASX winner after getting its drinks into China’s massive Freshippo market The Benchmark climbed early but sagged like a horrid old balloon to end the day around +0.5% Harris tells Credit Suisse “it’s not us, it’s you” an...

The ASX recovered from an early stumble to finish the day up-ish Meta wants you to pay $12 a month for the privilege of being a captive audience Some Big Names have had shockers as earnings relentlessly keep rolling in   The benchmark has...

The ASX 200 fell 0.21% and the ASX XEC slips 1.05% A 8 out of 11 sectors were lower led by Consumer Discretionary down 1.40% Energy sector and stocks rally after Russia announces plans to slash oil production   The ASX 200 dropped 0.21% t...

Exopharm (EX1) shares tumble following the company’s bid to raise $2.1 million The company signed a mandate on Sunday with Alto Capital and Canary Capital to secure the funds via a combination of a $600,000 convertible note, an entitleme...

ASX slumps even lower after lunch to end the day down around 0.5% China’s demands for the return of “weather balloon” debris met with hearty Pentagon chuckles Terramin’s bid to reopen a sub-winery mine shut down by the SA government   It’...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

With various studies identifying exosomes as a preferred drug-delivery option for some mRNA therapeutics, Exopharm is centre stage to be a leader in the field. You can sense the excitement of Exopharm (ASX:EX1) founder and CEO Dr Ian Dixon...

Exopharm will move to another important stage in a collaboration agreement with a major global pharmaceutical play, in the process reinforcing its position as a leader in exosome medicine delivery. Australian biopharma Exopharm (ASX:EX1) ha...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Alto Capital...

Exopharm’s technology has put the company in a leadership-position in both naïve exosomes and engineered exosomes as it progresses to a product-first company.  It’s been a challenging yet productive two years for the Exopharm (ASX:EX1) tea...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Dr Boreham’s Crucible By Tim Boreham ASX code: ((IIQ)) Share price: 67 cents Market cap: $59.8 million Shares on issue: 92,018,702 Chief executive officer: Dr Leearne Hinch Board: Dr Geoffrey Cumming (chair), Robert (Max) Johnston, Philip P...

With a rapidly growing global interest in the superpower of exosomes, major pharmaceutical deals and foundational patents, Exopharm is poised to become an essential part of the modern medicine ecosystem. As the only listed exosome compan...

Quarterlies: A data dump of intrigue and a smidgen of smoke and mirrors. But while the pain is akin to meeting your boyfriend’s parents, it always reveals a hell of a lot about the boy, inside the man. And so, Stockhead’s sublimely single b...

First up, ladies and gents, inflation has spiked way above what the RBA and everyone else was expecting. The headline consumer prices rose 5.1% over the year – consensus was looking at around 4.6% – which frankly would’ve been bad enough bu...

The ASX microcaps Emerging Companies index closed 0.01% higher on Friday Copper explorer Stelar Metals (ASX:SLB) led the market with a 57% gain US stock futures are trading flat ahead of the Friday open on Wall St   After a pretty strong...

The ASX200 has come to a jerky halt, closing more than 50 points or 0.7% higher. The market is down 5.6% over the last 52 weeks. The ASX Emerging Companies (XEC) index ended 0.6% better. The Four Horsemen of the Apocalypse are abroad on Mon...

Founded less than a decade ago with a mission to harness the unique properties of exosomes as a new class of medicine, Aussie-listed Exopharm has become a trailblazer in the exosome regenerative medical field. Australian technologist Dr Ian...

Exopharm (ASX:EX1) has signed a Master Collaborative Services Agreement with the Astellas Institute for Regenerative Medicine.

Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company Initial services will seek to validate Exopharm’s LEAP, LOAD and EVPS technology platforms to manufacture...

The granting of a US patent for Exopharm’s LEAP technology places the company in the top tier of global exosome producers. Exopharm (ASX: EX1) has saved the best ‘till Christmas, winning a US patent for its proprietary LEAP exosome purifica...

US Patent and Trademark Office has granted Exopharm patent US 11202805, for its LEAP exosome purification technology. LEAP enables large-scale, clinical grade commercial production of exosomes needed to underpin the emerging field of exos...

Exopharm Limited (EX1) announced the company has been granted a US patent for its proprietary LEAP exosome purification technology The company says the latest research points to exosomes as a better and safer way to deliver modern medicine...

Wall Street rallies as sentiment lifts US and European stock markets finally rose overnight after three days of losses. The global rebound followed more developments on the omicron front, as British PM Boris Johnson ruled out any lockdown b...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

MoneyTalks is Stockhead’s regular recap of the ASX stocks, sectors and trends that fund managers and analysts are looking at right now. Today, we hear from Paul Hart, executive director of Canary Capital.   Biotech is hot right now Hart sai...

The key appointments announced today will help Exopharm to engage international players, and support its ambitious goal to become a global exosome medicines company. Clinical stage biotech company, Exopharm (ASX:EX1), has appointed two new...

The ASX limped into the close on Friday, in a fairly tame finish to a roller-coaster week. Evergrande contagion fears and jitters ahead of the US Fed meeting sparked a sharp selloff on Monday. But a week (or three days) is a long time in ma...

ShareCafeA new cell technology for transformative medicine delivery Chris Baldwin – Deputy CEO & Chief Commercial Officer – Exopharm is a clinical-stage biopharmaceutical company using exosomes to deliver a new class of transformative...

ShareCafeHidden Gems Webinar Recap – BPH, EX1, RAP & PTX Catch up on the full webinar with presentations from BPH Energy (ASX: BPH), Exopharm (ASX: EX1), RessApp (ASX: RAP) & Prescient Therapeutics (ASX: GSS) Hidden Gems Webinar Re...

The patent for Exopharm’s LEAP technology has been granted by the Russian Patent Office. Exosome medicine company Exopharm (ASX: EX1) has taken a crucial step forward in the global strategy for its LEAP technology, with patent approval in R...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

Melbourne biotech company Exopharm (ASX:EX1) has received firm commitments from institutional and sophisticated investors to raise $12 million, double the minimum raise amount. The 16.7 million new shares will be priced at 72c, three times...